GlassScriptPhysician profile
Joseph A Nahas
NPI 1497903520
$6,295.29
in general payments reported to CMS, 2019-2025
34 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $125 · 2021: $461 · 2022: $1,015 · 2023: $1,396 · 2024: $916 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,061.74 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $683.32 | 2019-2025 | |
| Janssen Biotech, INC. | $591.03 | 2019-2025 | Tremfya, Stelara, Remicade |
| Aurinia Pharma U.S., INC. | $456.79 | 2021-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $302.28 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $257.14 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Mallinckrodt Hospital Products INC. | $202.51 | 2022-2023 | Acthar |
| Ucb, INC. | $202.01 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $197.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $183.34 | 2019-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $156.80 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $110.42 | 2022-2025 | |
| Genentech USA, INC. | $109.48 | 2019-2025 | Gazyva, Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.39 | 2019-2023 | Cyltezo |
| Novartis Pharmaceuticals Corporation | $88.44 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $84.39 | 2021-2024 | Absorica Ld, Winlevi, Ilumya |
| Mallinckrodt Enterprises LLC | $76.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.70 | 2019 | |
| Horizon Therapeutics Plc | $39.29 | 2019 | |
| Corcept Therapeutics | $39.05 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $37.98 | 2022 | |
| Sandoz INC. | $34.92 | 2023 | Hyrimoz |
| Celgene Corporation | $30.87 | 2019 | |
| Incyte Corporation | $30.69 | 2021-2024 | Opzelura |
| Alexion Pharmaceuticals, INC. | $30.25 | 2024 | Strensiq |
| Pharming Healthcare, INC. | $22.82 | 2023 | Ruconest |
| Medtronic, INC. | $18.57 | 2024 | Minimed 780g |
| Leo Pharma INC. | $16.42 | 2023 | Adbry |
| Fresenius Kabi USA, LLC | $15.25 | 2024 | Idacio |
| Genzyme Corporation | $14.10 | 2024 | |
| Tactile Systems Technology INC | $13.53 | 2023 | Flexitouch Plus, Entre Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.27 | 2019 | |
| Shire North American Group INC | $12.58 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nahas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.